Abstract:Peramivir, a neuraminidase inhibitor, was approved globally and is indicated for the treatment of uncomplicated influenza in adults and children. However, the only approved intravenous formulation of peramivir limits its clinical application due to the need for the specialized dosing techniques and increases the risk of contracting influenza virus infection among healthcare professionals when dosing within a short distance to the patient. The purpose of this study was to investigate the pharmacokinetic profile of peramivir in plasma and the lung of rats and to compare the profiles following administration through trans-nasal aerosol inhalation (0.0888, 0.1776, and 0.3552 mg/kg) and intravenous injection (30 mg/kg). The plasma concentration reached the Cmax within 1.0 h (upon inhalation) and decreased at a t1/2 of 6.71 and 10.9 h after inhalation and injection, respectively. The absolute bioavailability of peramivir after inhalation was 78.2 %. Overall, the pharmacokinetic exposure of peramivir in the lungs was higher than that in the plasma after aerosol inhalation. After inhalation, the Cmax of peramivir in the lung was achieved within 1.0 h, and the elimination of the drug was slower than in the case of intravenous injection with t1/2 values 1.81 h for injection and 5.72, 53.5, and 32.1 h for low, middle, and high doses administered through inhalation. The Cmax and AUC0-t values for peramivir in the lungs increased linearly with the increased inhalation dose. The results elucidate the pharmacokinetic process of peramivir after trans-nasal aerosol inhalation to rats and provide useful information for further rational application of this drug formulation.

Pharmacokinetics of peramivir after single intravenous doses in healthy Chinese subjects.

Pharmacokinetics of peramivir trihydrate and sodium chloride injection in Chinese healthy volunteers

Pharmacokinetic behavior of peramivir in the plasma and lungs of rats after trans-nasal aerosol inhalation and intravenous injection

Tolerability Trial of Peramivir Trihydrate and Sodium Chloride Injection in Healthy Volunteers

Pharmacokinetics and Safety of Pitavastatin Calcium Tablets in Chinese Healthy Volunteers after a Single Oral Dose Administration

[Pharmacokinetics and Relative Bioavailability of Ziprasidone Tablets in Chinese Healthy Volunteers].

The pharmacokinetics of lamivudine in healthy Chinese subjects: Short report

Virological response to peramivir treatment in adults hospitalised for influenza-associated lower respiratory tract infections

Clinical efficacy and safety of peramivir trihydrate sodium chloride injection in the treatment of acute simple uncomplicated influenza

A randomized controlled study of peramivir, oseltamivir and placebo in patients with mild influenza

Pharmacokinetic characteristics of single-dose pidotimod injection in Chinese healthy volunteers

Pharmacokinetics of Meropenem Single Dose Intravenous in Healthy Volunteers

Clinical Effectiveness of Intravenous Peramivir Compared With Oseltamivir in Patients With Severe Influenza A With Primary Viral Pneumonia: A Randomized Controlled Study

Pharmacokinetics of Tenofovir Disoproxil Fumarate Tablets in Healthy Volunteers from Western China

Pharmacokinetics of biapenem injection after a single dose administration in Chinese healthy subjects

Pharmacokinetics of single dose ampiroxicam tablet in Chinese healthy subjects

Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study

A First-in-human Safety, Tolerability and Pharmacokinetics study of Benapenem in Healthy Chinese Volunteers.

Pharmacokinetics of ribavirin tablets in healthy volunteers

Pharmacokinetics of Single and Multiple Doses of Biapenem for Injection in Chinese Healthy Volunteers with Intravenous Administration

A Retrospective Analysis of Three Antiviral Regimens of Peramivir in the Treatment of Severe Influenza A with Primary Viral Pneumonia